Product
SYN125
1 clinical trial
2 indications
Indication
Epithelial CarcinomaIndication
Solid TumorClinical trial
A Phase 1 Dose Escalation Trial of SYN125 Single Agent in Solid Tumors and in Combination With Fixed Dose SYN004 in Patients With Epithelial Cancers With EGFR Expressions.Status: Active (not recruiting), Estimated PCD: 2023-07-31